Janet Rader
Concepts (647)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 85 | 2025 | 299 | 12.700 |
Why?
| | Papillomavirus Infections | 19 | 2025 | 173 | 2.900 |
Why?
| | Ovarian Neoplasms | 37 | 2024 | 459 | 2.730 |
Why?
| | Endometrial Neoplasms | 34 | 2019 | 144 | 2.360 |
Why?
| | Uterine Cervical Dysplasia | 16 | 2017 | 51 | 2.340 |
Why?
| | Carcinoma, Squamous Cell | 31 | 2018 | 332 | 1.970 |
Why?
| | Gene Expression Regulation, Neoplastic | 19 | 2025 | 857 | 1.870 |
Why?
| | Human papillomavirus 16 | 8 | 2019 | 44 | 1.690 |
Why?
| | Papillomaviridae | 17 | 2025 | 105 | 1.580 |
Why?
| | Female | 191 | 2025 | 28171 | 1.530 |
Why?
| | Gene Expression Profiling | 9 | 2021 | 1105 | 1.480 |
Why?
| | DNA Methylation | 22 | 2025 | 592 | 1.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 17 | 2013 | 1031 | 1.260 |
Why?
| | Genital Neoplasms, Female | 10 | 2018 | 48 | 1.160 |
Why?
| | Human papillomavirus 18 | 5 | 2019 | 9 | 1.150 |
Why?
| | Humans | 194 | 2025 | 52483 | 1.130 |
Why?
| | Genetic Predisposition to Disease | 14 | 2024 | 528 | 1.090 |
Why?
| | Adult | 92 | 2024 | 14161 | 1.050 |
Why?
| | Neoplasm Staging | 41 | 2019 | 772 | 1.010 |
Why?
| | Middle Aged | 99 | 2024 | 13028 | 0.990 |
Why?
| | Adenocarcinoma | 18 | 2018 | 405 | 0.970 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 505 | 0.940 |
Why?
| | Fluorodeoxyglucose F18 | 15 | 2022 | 188 | 0.930 |
Why?
| | DNA-Binding Proteins | 9 | 2021 | 422 | 0.920 |
Why?
| | MicroRNAs | 7 | 2019 | 387 | 0.900 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 649 | 0.900 |
Why?
| | Carcinoma | 12 | 2010 | 138 | 0.880 |
Why?
| | Oncogene Proteins, Viral | 4 | 2019 | 54 | 0.830 |
Why?
| | Radiopharmaceuticals | 14 | 2022 | 204 | 0.780 |
Why?
| | Cervix Uteri | 7 | 2017 | 49 | 0.780 |
Why?
| | Repressor Proteins | 4 | 2019 | 155 | 0.780 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 13 | 0.740 |
Why?
| | DNA, Viral | 6 | 2019 | 137 | 0.720 |
Why?
| | Cell Line, Tumor | 18 | 2021 | 1470 | 0.700 |
Why?
| | Immunologic Factors | 2 | 2014 | 117 | 0.700 |
Why?
| | Neoplasm Invasiveness | 15 | 2020 | 278 | 0.680 |
Why?
| | Neoplasms | 8 | 2022 | 1325 | 0.660 |
Why?
| | Genetic Markers | 8 | 2017 | 109 | 0.650 |
Why?
| | Genes, Tumor Suppressor | 8 | 2007 | 74 | 0.650 |
Why?
| | Neoplasm Proteins | 10 | 2019 | 334 | 0.640 |
Why?
| | Immunoglobulins | 3 | 2017 | 76 | 0.640 |
Why?
| | Aged | 70 | 2024 | 10121 | 0.640 |
Why?
| | Genomics | 4 | 2018 | 268 | 0.620 |
Why?
| | Gene Silencing | 5 | 2018 | 118 | 0.600 |
Why?
| | Biomedical Research | 1 | 2022 | 256 | 0.600 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2017 | 182 | 0.540 |
Why?
| | Cisplatin | 7 | 2022 | 285 | 0.530 |
Why?
| | Proteomics | 1 | 2019 | 329 | 0.530 |
Why?
| | Promoter Regions, Genetic | 12 | 2020 | 467 | 0.510 |
Why?
| | Aged, 80 and over | 36 | 2024 | 3392 | 0.510 |
Why?
| | HLA-C Antigens | 2 | 2018 | 5 | 0.500 |
Why?
| | Receptors, KIR | 2 | 2018 | 12 | 0.500 |
Why?
| | Positron-Emission Tomography | 11 | 2013 | 301 | 0.480 |
Why?
| | Ubiquitin Thiolesterase | 2 | 2021 | 19 | 0.480 |
Why?
| | Lymph Nodes | 10 | 2010 | 258 | 0.480 |
Why?
| | Tumor Virus Infections | 4 | 2006 | 48 | 0.480 |
Why?
| | Microsatellite Repeats | 14 | 2007 | 42 | 0.480 |
Why?
| | Alleles | 6 | 2025 | 276 | 0.480 |
Why?
| | Disease-Free Survival | 17 | 2013 | 460 | 0.470 |
Why?
| | Hysterectomy | 15 | 2022 | 90 | 0.470 |
Why?
| | Gynecologic Surgical Procedures | 4 | 2010 | 28 | 0.470 |
Why?
| | Virus Integration | 3 | 2025 | 9 | 0.460 |
Why?
| | Granulosa Cell Tumor | 2 | 2024 | 3 | 0.450 |
Why?
| | Phenotype | 5 | 2016 | 789 | 0.440 |
Why?
| | Prognosis | 19 | 2021 | 2099 | 0.430 |
Why?
| | Lymphatic Metastasis | 14 | 2019 | 220 | 0.430 |
Why?
| | Chromosomes, Human, Pair 6 | 4 | 2007 | 15 | 0.430 |
Why?
| | Immunohistochemistry | 13 | 2024 | 979 | 0.420 |
Why?
| | Nuclear Proteins | 8 | 2009 | 245 | 0.420 |
Why?
| | Loss of Heterozygosity | 10 | 2007 | 78 | 0.420 |
Why?
| | Ovary | 2 | 2008 | 107 | 0.400 |
Why?
| | Membrane Proteins | 3 | 2005 | 335 | 0.390 |
Why?
| | Genotype | 9 | 2018 | 566 | 0.390 |
Why?
| | Survival Analysis | 14 | 2021 | 673 | 0.380 |
Why?
| | STAT3 Transcription Factor | 3 | 2021 | 85 | 0.380 |
Why?
| | Cell Movement | 5 | 2021 | 268 | 0.380 |
Why?
| | Ultrasonic Therapy | 3 | 2001 | 33 | 0.370 |
Why?
| | Peritoneal Neoplasms | 4 | 2008 | 65 | 0.370 |
Why?
| | Carcinoma, Endometrioid | 6 | 2014 | 38 | 0.370 |
Why?
| | Genes, p53 | 2 | 2010 | 52 | 0.370 |
Why?
| | Cell Proliferation | 6 | 2021 | 1023 | 0.360 |
Why?
| | Signal Transduction | 8 | 2021 | 1671 | 0.350 |
Why?
| | Risk Factors | 13 | 2019 | 3889 | 0.350 |
Why?
| | Uterine Neoplasms | 5 | 2009 | 60 | 0.350 |
Why?
| | Mutation | 12 | 2018 | 1347 | 0.340 |
Why?
| | Carboplatin | 2 | 2009 | 57 | 0.340 |
Why?
| | Ascites | 2 | 2008 | 32 | 0.340 |
Why?
| | Antibodies, Monoclonal | 5 | 2021 | 481 | 0.340 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2010 | 13 | 0.340 |
Why?
| | Antineoplastic Agents | 9 | 2014 | 1222 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 13 | 0.340 |
Why?
| | Cohort Studies | 13 | 2024 | 1542 | 0.330 |
Why?
| | Base Sequence | 8 | 2019 | 640 | 0.330 |
Why?
| | Membrane Glycoproteins | 2 | 2009 | 244 | 0.330 |
Why?
| | GTPase-Activating Proteins | 1 | 2009 | 25 | 0.330 |
Why?
| | Disease Progression | 6 | 2020 | 871 | 0.330 |
Why?
| | DNA, Neoplasm | 11 | 2006 | 146 | 0.320 |
Why?
| | Chromosomes, Human, Pair 11 | 3 | 2005 | 55 | 0.320 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2009 | 87 | 0.320 |
Why?
| | Neoplasms, Glandular and Epithelial | 3 | 2006 | 41 | 0.320 |
Why?
| | Brachytherapy | 9 | 2014 | 48 | 0.310 |
Why?
| | Combined Modality Therapy | 11 | 2010 | 639 | 0.310 |
Why?
| | Abdominal Neoplasms | 1 | 2009 | 16 | 0.310 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2021 | 53 | 0.310 |
Why?
| | Genome, Human | 3 | 2025 | 121 | 0.310 |
Why?
| | DNA Repair | 11 | 2007 | 195 | 0.310 |
Why?
| | Laser Coagulation | 1 | 2009 | 27 | 0.310 |
Why?
| | Retrospective Studies | 33 | 2024 | 6607 | 0.300 |
Why?
| | Drug Administration Schedule | 10 | 2013 | 374 | 0.300 |
Why?
| | Homeodomain Proteins | 2 | 2006 | 80 | 0.300 |
Why?
| | Deoxycytidine | 4 | 2006 | 29 | 0.290 |
Why?
| | RNA-Binding Proteins | 2 | 2021 | 128 | 0.290 |
Why?
| | Microsatellite Instability | 5 | 2019 | 21 | 0.290 |
Why?
| | Protozoan Proteins | 1 | 2008 | 32 | 0.290 |
Why?
| | Germ-Line Mutation | 3 | 2024 | 66 | 0.290 |
Why?
| | Laparoscopy | 3 | 2022 | 180 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 483 | 0.290 |
Why?
| | Ovariectomy | 7 | 2010 | 113 | 0.280 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 326 | 0.280 |
Why?
| | Antigens, CD | 2 | 2007 | 218 | 0.280 |
Why?
| | Chromosomes, Human, Pair 3 | 4 | 2001 | 19 | 0.270 |
Why?
| | SOXC Transcription Factors | 2 | 2019 | 13 | 0.270 |
Why?
| | Polymerase Chain Reaction | 9 | 2010 | 461 | 0.270 |
Why?
| | Heart Arrest | 1 | 2009 | 158 | 0.270 |
Why?
| | Receptors, Estrogen | 3 | 2024 | 131 | 0.260 |
Why?
| | Topotecan | 5 | 2013 | 17 | 0.260 |
Why?
| | POU Domain Factors | 1 | 2006 | 1 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 405 | 0.250 |
Why?
| | Vulvar Neoplasms | 5 | 2002 | 60 | 0.250 |
Why?
| | Neoplasm Metastasis | 5 | 2021 | 243 | 0.250 |
Why?
| | HeLa Cells | 3 | 2021 | 265 | 0.250 |
Why?
| | Registries | 6 | 2010 | 581 | 0.250 |
Why?
| | Anemia | 3 | 2020 | 74 | 0.240 |
Why?
| | Genome, Viral | 2 | 2025 | 83 | 0.240 |
Why?
| | Survival Rate | 10 | 2009 | 945 | 0.240 |
Why?
| | Vaginal Smears | 6 | 2006 | 28 | 0.240 |
Why?
| | Breast Neoplasms | 5 | 2018 | 1212 | 0.240 |
Why?
| | Young Adult | 7 | 2018 | 4329 | 0.240 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2007 | 582 | 0.230 |
Why?
| | Gene Rearrangement | 1 | 2025 | 75 | 0.230 |
Why?
| | Chromosome Aberrations | 1 | 2006 | 297 | 0.230 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2004 | 61 | 0.220 |
Why?
| | Receptors, Androgen | 1 | 2024 | 46 | 0.220 |
Why?
| | Receptors, Progesterone | 1 | 2024 | 66 | 0.220 |
Why?
| | Cystadenocarcinoma, Papillary | 2 | 2002 | 14 | 0.210 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 16 | 0.210 |
Why?
| | Oncostatin M | 2 | 2021 | 5 | 0.210 |
Why?
| | Quinazolines | 1 | 2003 | 34 | 0.210 |
Why?
| | Antigens, Neoplasm | 1 | 2004 | 147 | 0.210 |
Why?
| | Polymorphism, Genetic | 5 | 2018 | 185 | 0.210 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 186 | 0.210 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2023 | 30 | 0.200 |
Why?
| | Omentum | 1 | 2002 | 16 | 0.200 |
Why?
| | Case-Control Studies | 7 | 2019 | 1201 | 0.200 |
Why?
| | Chromosome Deletion | 3 | 2000 | 142 | 0.200 |
Why?
| | Treatment Outcome | 23 | 2014 | 5422 | 0.200 |
Why?
| | Linkage Disequilibrium | 3 | 2017 | 39 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2014 | 169 | 0.190 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 125 | 0.190 |
Why?
| | Genetic Variation | 4 | 2019 | 230 | 0.190 |
Why?
| | Eukaryotic Initiation Factor-4F | 1 | 2021 | 1 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2013 | 236 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 256 | 0.190 |
Why?
| | CA-125 Antigen | 3 | 2008 | 16 | 0.190 |
Why?
| | Base Pair Mismatch | 5 | 2006 | 21 | 0.190 |
Why?
| | Suction | 1 | 2001 | 24 | 0.190 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 50 | 0.190 |
Why?
| | Oncostatin M Receptor beta Subunit | 1 | 2021 | 1 | 0.190 |
Why?
| | Postoperative Complications | 3 | 2022 | 1068 | 0.190 |
Why?
| | Smoking | 1 | 2005 | 520 | 0.180 |
Why?
| | Radiotherapy, Conformal | 2 | 2014 | 53 | 0.180 |
Why?
| | Proteins | 5 | 2008 | 348 | 0.180 |
Why?
| | Carcinoma in Situ | 2 | 2013 | 72 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 8 | 2007 | 202 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2002 | 39 | 0.180 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 111 | 0.170 |
Why?
| | Fetofetal Transfusion | 1 | 2020 | 6 | 0.170 |
Why?
| | Polycythemia | 1 | 2020 | 9 | 0.170 |
Why?
| | Radiotherapy | 3 | 2010 | 127 | 0.170 |
Why?
| | Pregnancy, Twin | 1 | 2020 | 8 | 0.170 |
Why?
| | Minority Groups | 1 | 2022 | 135 | 0.170 |
Why?
| | Twins, Monozygotic | 1 | 2020 | 16 | 0.170 |
Why?
| | Colorectal Neoplasms | 3 | 2002 | 294 | 0.170 |
Why?
| | Lymph Node Excision | 7 | 2019 | 133 | 0.170 |
Why?
| | Sarcoma | 3 | 2009 | 72 | 0.170 |
Why?
| | Genetic Diseases, Inborn | 1 | 2000 | 24 | 0.170 |
Why?
| | Patient Satisfaction | 2 | 2006 | 284 | 0.170 |
Why?
| | Receptor, erbB-3 | 1 | 2020 | 2 | 0.170 |
Why?
| | Furin | 1 | 2020 | 3 | 0.170 |
Why?
| | HLA-DQ Antigens | 1 | 2000 | 3 | 0.170 |
Why?
| | Phosphoproteins | 2 | 2016 | 119 | 0.170 |
Why?
| | Receptor, IGF Type 1 | 1 | 2020 | 22 | 0.170 |
Why?
| | Transcriptome | 2 | 2020 | 370 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 7 | 2013 | 1165 | 0.160 |
Why?
| | Mice, Nude | 4 | 2021 | 265 | 0.160 |
Why?
| | Prenatal Diagnosis | 1 | 2020 | 103 | 0.160 |
Why?
| | Tumor Cells, Cultured | 7 | 2021 | 460 | 0.160 |
Why?
| | RNA, Neoplasm | 3 | 2007 | 45 | 0.160 |
Why?
| | Antibodies, Neoplasm | 1 | 2019 | 28 | 0.160 |
Why?
| | Students | 1 | 2022 | 228 | 0.160 |
Why?
| | Papillomavirus E7 Proteins | 2 | 2017 | 32 | 0.160 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2019 | 4 | 0.160 |
Why?
| | Adolescent | 13 | 2018 | 6739 | 0.160 |
Why?
| | Reproducibility of Results | 2 | 2022 | 1229 | 0.160 |
Why?
| | Placenta | 1 | 2020 | 153 | 0.150 |
Why?
| | Indocyanine Green | 1 | 2019 | 33 | 0.150 |
Why?
| | Follow-Up Studies | 13 | 2019 | 2279 | 0.150 |
Why?
| | Doxorubicin | 4 | 2009 | 241 | 0.150 |
Why?
| | Fallopian Tube Neoplasms | 3 | 2008 | 15 | 0.150 |
Why?
| | Decision Making | 1 | 2001 | 282 | 0.150 |
Why?
| | Salvage Therapy | 3 | 2008 | 136 | 0.150 |
Why?
| | Cyclooxygenase 2 | 2 | 2017 | 48 | 0.150 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 229 | 0.140 |
Why?
| | Transcription Factors | 1 | 2021 | 566 | 0.140 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 5 | 0.140 |
Why?
| | HLA-B Antigens | 1 | 2017 | 8 | 0.140 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 93 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2023 | 636 | 0.140 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 117 | 0.140 |
Why?
| | Receptors, Vitronectin | 1 | 1997 | 1 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 3 | 2005 | 130 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 5 | 2004 | 151 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 3 | 2009 | 9 | 0.140 |
Why?
| | DNA Mutational Analysis | 9 | 2005 | 180 | 0.140 |
Why?
| | Interleukin-10 | 1 | 2017 | 84 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2017 | 121 | 0.140 |
Why?
| | In Situ Hybridization | 3 | 2008 | 64 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 123 | 0.130 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2017 | 21 | 0.130 |
Why?
| | Protein Binding | 1 | 2019 | 667 | 0.130 |
Why?
| | Animals | 11 | 2021 | 13505 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2019 | 204 | 0.130 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2017 | 49 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2009 | 184 | 0.130 |
Why?
| | Risk Assessment | 9 | 2019 | 1327 | 0.130 |
Why?
| | Radiotherapy Dosage | 8 | 2014 | 255 | 0.130 |
Why?
| | Body Mass Index | 3 | 2010 | 689 | 0.130 |
Why?
| | Radiation Injuries | 3 | 2008 | 110 | 0.130 |
Why?
| | Diagnosis, Differential | 4 | 2024 | 1046 | 0.130 |
Why?
| | Taxoids | 3 | 2006 | 37 | 0.130 |
Why?
| | ROC Curve | 1 | 2017 | 253 | 0.130 |
Why?
| | Carrier Proteins | 7 | 2006 | 313 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2017 | 1567 | 0.130 |
Why?
| | Biopsy | 5 | 2006 | 605 | 0.130 |
Why?
| | Estrogens | 1 | 2017 | 223 | 0.120 |
Why?
| | Prospective Studies | 10 | 2019 | 2481 | 0.120 |
Why?
| | Colposcopy | 3 | 2006 | 17 | 0.120 |
Why?
| | Molecular Sequence Data | 5 | 2009 | 778 | 0.120 |
Why?
| | Mice | 7 | 2021 | 5949 | 0.120 |
Why?
| | Wound Healing | 2 | 2018 | 219 | 0.120 |
Why?
| | Carcinosarcoma | 3 | 2019 | 18 | 0.120 |
Why?
| | Apoptosis | 2 | 2021 | 1119 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2017 | 713 | 0.120 |
Why?
| | Sensitivity and Specificity | 4 | 2006 | 891 | 0.120 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 1995 | 33 | 0.120 |
Why?
| | Aneurysm | 1 | 1995 | 31 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2008 | 1378 | 0.120 |
Why?
| | Algorithms | 1 | 2019 | 672 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 227 | 0.120 |
Why?
| | DNA Primers | 2 | 2006 | 208 | 0.120 |
Why?
| | Platinum Compounds | 4 | 2008 | 11 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2014 | 151 | 0.110 |
Why?
| | Obesity | 5 | 2010 | 1162 | 0.110 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2014 | 5 | 0.110 |
Why?
| | Cyclohexanones | 1 | 2014 | 5 | 0.110 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2004 | 11 | 0.110 |
Why?
| | Embolization, Therapeutic | 1 | 1995 | 88 | 0.110 |
Why?
| | Transcriptional Activation | 2 | 2019 | 122 | 0.110 |
Why?
| | Camptothecin | 3 | 2010 | 15 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 80 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2014 | 122 | 0.110 |
Why?
| | Introns | 1 | 2013 | 53 | 0.110 |
Why?
| | Hypercalcemia | 1 | 1993 | 34 | 0.110 |
Why?
| | Paclitaxel | 4 | 2007 | 89 | 0.110 |
Why?
| | Decision Support Techniques | 2 | 2010 | 70 | 0.100 |
Why?
| | Chromosome Mapping | 3 | 2005 | 154 | 0.100 |
Why?
| | Pyridines | 1 | 2014 | 132 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2006 | 184 | 0.100 |
Why?
| | Dermatologic Surgical Procedures | 1 | 1992 | 35 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2016 | 291 | 0.100 |
Why?
| | Models, Genetic | 1 | 2012 | 169 | 0.100 |
Why?
| | Tomography, Emission-Computed | 4 | 2005 | 53 | 0.100 |
Why?
| | Groin | 2 | 2002 | 16 | 0.100 |
Why?
| | Keratinocytes | 2 | 2006 | 93 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2021 | 1132 | 0.090 |
Why?
| | Glucose | 1 | 2014 | 355 | 0.090 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 73 | 0.090 |
Why?
| | Laser Therapy | 1 | 1992 | 82 | 0.090 |
Why?
| | Exons | 3 | 2007 | 102 | 0.090 |
Why?
| | Pyrazoles | 2 | 2023 | 114 | 0.090 |
Why?
| | Infusions, Intravenous | 4 | 2006 | 220 | 0.090 |
Why?
| | Heterozygote | 2 | 2004 | 90 | 0.090 |
Why?
| | Condylomata Acuminata | 1 | 1991 | 4 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 3 | 2014 | 1546 | 0.090 |
Why?
| | Models, Statistical | 1 | 2012 | 230 | 0.090 |
Why?
| | Epithelium | 2 | 2007 | 65 | 0.090 |
Why?
| | Goserelin | 1 | 2010 | 1 | 0.090 |
Why?
| | Decision Trees | 1 | 2010 | 22 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 21 | 0.090 |
Why?
| | Ileal Diseases | 1 | 1990 | 4 | 0.090 |
Why?
| | Predictive Value of Tests | 6 | 2010 | 944 | 0.090 |
Why?
| | Leiomyoma | 1 | 1990 | 23 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2009 | 665 | 0.080 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2010 | 66 | 0.080 |
Why?
| | Restriction Mapping | 3 | 2006 | 33 | 0.080 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 406 | 0.080 |
Why?
| | Colonic Neoplasms | 2 | 2004 | 163 | 0.080 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1990 | 89 | 0.080 |
Why?
| | Skin Transplantation | 1 | 1990 | 44 | 0.080 |
Why?
| | Down-Regulation | 4 | 2020 | 346 | 0.080 |
Why?
| | Age Factors | 4 | 2006 | 1132 | 0.080 |
Why?
| | Maximum Tolerated Dose | 5 | 2010 | 39 | 0.080 |
Why?
| | Fluorouracil | 2 | 2006 | 59 | 0.080 |
Why?
| | Endometrium | 3 | 2019 | 43 | 0.080 |
Why?
| | Urinary Bladder Diseases | 1 | 2009 | 18 | 0.080 |
Why?
| | Intestinal Diseases | 1 | 2009 | 26 | 0.080 |
Why?
| | Lasers, Gas | 1 | 2009 | 6 | 0.080 |
Why?
| | Embolism, Air | 1 | 2009 | 10 | 0.080 |
Why?
| | Transcription, Genetic | 4 | 2019 | 378 | 0.080 |
Why?
| | Lymphatic Vessels | 1 | 2009 | 55 | 0.080 |
Why?
| | Vaginal Neoplasms | 2 | 2005 | 5 | 0.080 |
Why?
| | Adenocarcinoma, Clear Cell | 3 | 2019 | 34 | 0.080 |
Why?
| | Fluorine Radioisotopes | 1 | 2008 | 25 | 0.080 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2008 | 4 | 0.080 |
Why?
| | Infertility, Female | 1 | 2008 | 19 | 0.080 |
Why?
| | Eimeria | 1 | 2008 | 3 | 0.070 |
Why?
| | Haplotypes | 2 | 2017 | 92 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2006 | 90 | 0.070 |
Why?
| | Up-Regulation | 2 | 2020 | 454 | 0.070 |
Why?
| | Ubiquitin | 1 | 2008 | 47 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 169 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 2 | 2006 | 183 | 0.070 |
Why?
| | Cricetinae | 1 | 2008 | 194 | 0.070 |
Why?
| | Tumor Burden | 2 | 2021 | 136 | 0.070 |
Why?
| | Expressed Sequence Tags | 1 | 2007 | 8 | 0.070 |
Why?
| | Infusion Pumps | 1 | 1987 | 13 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 181 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 111 | 0.070 |
Why?
| | Microdissection | 1 | 2007 | 19 | 0.070 |
Why?
| | Models, Biological | 2 | 2008 | 735 | 0.070 |
Why?
| | Precancerous Conditions | 2 | 2005 | 85 | 0.070 |
Why?
| | MutS Homolog 2 Protein | 5 | 2007 | 12 | 0.070 |
Why?
| | Aorta | 3 | 2005 | 165 | 0.070 |
Why?
| | Stromal Cells | 1 | 2007 | 79 | 0.070 |
Why?
| | Organ Specificity | 2 | 2018 | 115 | 0.070 |
Why?
| | Lasers | 1 | 2007 | 108 | 0.070 |
Why?
| | Codon | 2 | 2003 | 43 | 0.070 |
Why?
| | Pelvic Floor | 1 | 2007 | 52 | 0.070 |
Why?
| | Recombinant Proteins | 1 | 2008 | 483 | 0.070 |
Why?
| | Neutropenia | 1 | 2007 | 115 | 0.070 |
Why?
| | RNA, Double-Stranded | 1 | 2006 | 23 | 0.070 |
Why?
| | Polymorphism, Single-Stranded Conformational | 6 | 2003 | 19 | 0.070 |
Why?
| | Tissue Fixation | 1 | 2006 | 36 | 0.070 |
Why?
| | Intestinal Perforation | 2 | 2006 | 24 | 0.060 |
Why?
| | Pulmonary Embolism | 1 | 1987 | 86 | 0.060 |
Why?
| | Specimen Handling | 1 | 2006 | 56 | 0.060 |
Why?
| | Head and Neck Neoplasms | 2 | 2016 | 288 | 0.060 |
Why?
| | Protein Kinases | 1 | 2006 | 72 | 0.060 |
Why?
| | Chromosomes, Artificial, Yeast | 3 | 2000 | 7 | 0.060 |
Why?
| | Endometrial Hyperplasia | 2 | 2002 | 14 | 0.060 |
Why?
| | Abdomen | 1 | 2006 | 75 | 0.060 |
Why?
| | Proportional Hazards Models | 4 | 2010 | 443 | 0.060 |
Why?
| | Papillomavirus Vaccines | 1 | 2006 | 70 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 153 | 0.060 |
Why?
| | Recurrence | 4 | 2010 | 672 | 0.060 |
Why?
| | Probability | 4 | 2007 | 172 | 0.060 |
Why?
| | Dibenzocycloheptenes | 1 | 2004 | 1 | 0.060 |
Why?
| | Terminal Care | 1 | 2005 | 48 | 0.060 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2005 | 52 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 86 | 0.060 |
Why?
| | Quinolines | 1 | 2004 | 44 | 0.060 |
Why?
| | Male | 11 | 2018 | 26761 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 221 | 0.060 |
Why?
| | Amyloid | 1 | 2004 | 36 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2004 | 171 | 0.050 |
Why?
| | Genes, Viral | 1 | 2003 | 39 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 235 | 0.050 |
Why?
| | Lactones | 1 | 2003 | 25 | 0.050 |
Why?
| | Abdomen, Acute | 1 | 2003 | 6 | 0.050 |
Why?
| | Biopsy, Needle | 4 | 2006 | 183 | 0.050 |
Why?
| | Thrombospondins | 1 | 2003 | 10 | 0.050 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 58 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2023 | 19 | 0.050 |
Why?
| | RNA, Viral | 2 | 2016 | 127 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2004 | 87 | 0.050 |
Why?
| | Clinical Competence | 1 | 2006 | 406 | 0.050 |
Why?
| | Fibroma | 1 | 2003 | 40 | 0.050 |
Why?
| | Neoplasms, Second Primary | 1 | 2004 | 77 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2010 | 63 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2004 | 118 | 0.050 |
Why?
| | Uterine Hemorrhage | 1 | 2002 | 11 | 0.050 |
Why?
| | Age of Onset | 2 | 2004 | 110 | 0.050 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2002 | 7 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 2 | 2019 | 55 | 0.050 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 26 | 0.050 |
Why?
| | Blood Transfusion, Autologous | 1 | 2002 | 4 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2003 | 339 | 0.050 |
Why?
| | Genital Diseases, Female | 1 | 2002 | 17 | 0.050 |
Why?
| | Blood Donors | 1 | 2002 | 21 | 0.050 |
Why?
| | Acridines | 1 | 2002 | 4 | 0.050 |
Why?
| | Pregnancy | 3 | 2020 | 2680 | 0.050 |
Why?
| | Postmenopause | 1 | 2002 | 82 | 0.050 |
Why?
| | Medical History Taking | 1 | 2002 | 47 | 0.050 |
Why?
| | Medical Records | 1 | 2002 | 87 | 0.050 |
Why?
| | Complementary Therapies | 1 | 2002 | 25 | 0.050 |
Why?
| | Family Health | 1 | 2002 | 79 | 0.050 |
Why?
| | AU Rich Elements | 1 | 2021 | 2 | 0.050 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 2021 | 15 | 0.050 |
Why?
| | RNA Stability | 1 | 2021 | 25 | 0.050 |
Why?
| | Cytokine Receptor gp130 | 1 | 2021 | 14 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2021 | 55 | 0.050 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2001 | 29 | 0.050 |
Why?
| | Lymphatic Irradiation | 1 | 2001 | 1 | 0.050 |
Why?
| | Blotting, Northern | 2 | 2001 | 106 | 0.050 |
Why?
| | Diet Records | 1 | 2001 | 18 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 25 | 0.040 |
Why?
| | Blotting, Southern | 3 | 2002 | 42 | 0.040 |
Why?
| | Internship and Residency | 1 | 2006 | 448 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 220 | 0.040 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2000 | 23 | 0.040 |
Why?
| | Blood Vessels | 1 | 2001 | 71 | 0.040 |
Why?
| | Equipment Design | 1 | 2001 | 293 | 0.040 |
Why?
| | Catheterization, Central Venous | 1 | 2001 | 84 | 0.040 |
Why?
| | Uganda | 1 | 2020 | 38 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2001 | 66 | 0.040 |
Why?
| | Isoenzymes | 1 | 2001 | 166 | 0.040 |
Why?
| | Risk Management | 1 | 2000 | 31 | 0.040 |
Why?
| | Logistic Models | 2 | 2017 | 925 | 0.040 |
Why?
| | Physical Chromosome Mapping | 1 | 2000 | 8 | 0.040 |
Why?
| | Quality Improvement | 1 | 2022 | 226 | 0.040 |
Why?
| | Incidence | 3 | 2007 | 1062 | 0.040 |
Why?
| | Dietary Fats | 1 | 2001 | 130 | 0.040 |
Why?
| | beta Karyopherins | 1 | 2019 | 4 | 0.040 |
Why?
| | Patient Discharge | 1 | 2022 | 330 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2001 | 275 | 0.040 |
Why?
| | Acid Anhydride Hydrolases | 1 | 1999 | 14 | 0.040 |
Why?
| | Cell Survival | 1 | 2021 | 612 | 0.040 |
Why?
| | DNA Repair Enzymes | 1 | 1999 | 43 | 0.040 |
Why?
| | Adenosine Triphosphatases | 1 | 1999 | 91 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2019 | 187 | 0.040 |
Why?
| | Regression Analysis | 3 | 2006 | 401 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 1678 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 69 | 0.040 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 1998 | 4 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 133 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 250 | 0.040 |
Why?
| | Gene Dosage | 1 | 2018 | 78 | 0.040 |
Why?
| | Histone Demethylases | 1 | 2018 | 19 | 0.040 |
Why?
| | Th1-Th2 Balance | 1 | 2018 | 2 | 0.040 |
Why?
| | Leptin | 1 | 2019 | 148 | 0.040 |
Why?
| | Estradiol | 1 | 2019 | 214 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2018 | 83 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2017 | 13 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 57 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 21 | 0.040 |
Why?
| | Chemokines | 1 | 2017 | 79 | 0.030 |
Why?
| | Receptors, Collagen | 1 | 1997 | 3 | 0.030 |
Why?
| | Receptors, Fibronectin | 1 | 1997 | 5 | 0.030 |
Why?
| | Time Factors | 4 | 2010 | 2968 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2017 | 144 | 0.030 |
Why?
| | Mass Screening | 1 | 2000 | 357 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2018 | 180 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 138 | 0.030 |
Why?
| | Child | 4 | 2018 | 7248 | 0.030 |
Why?
| | Integrins | 1 | 1997 | 31 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2010 | 124 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 2 | 2010 | 66 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 236 | 0.030 |
Why?
| | Epithelial Cells | 2 | 2006 | 215 | 0.030 |
Why?
| | Hepatitis Viruses | 1 | 2016 | 2 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 747 | 0.030 |
Why?
| | Herpesviridae | 1 | 2016 | 19 | 0.030 |
Why?
| | Viruses | 1 | 2016 | 25 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 144 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2017 | 552 | 0.030 |
Why?
| | Pilot Projects | 3 | 2004 | 721 | 0.030 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2016 | 42 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2010 | 267 | 0.030 |
Why?
| | DNA Replication | 1 | 1997 | 160 | 0.030 |
Why?
| | Baths | 1 | 1995 | 5 | 0.030 |
Why?
| | Plasmids | 2 | 2001 | 163 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 100 | 0.030 |
Why?
| | Central Nervous System Neoplasms | 1 | 2016 | 68 | 0.030 |
Why?
| | Fibroblasts | 1 | 2017 | 355 | 0.030 |
Why?
| | Electrosurgery | 1 | 1995 | 9 | 0.030 |
Why?
| | Macrophages | 1 | 2018 | 379 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 1998 | 398 | 0.030 |
Why?
| | DNA Probes, HPV | 2 | 1991 | 3 | 0.030 |
Why?
| | CpG Islands | 2 | 2008 | 121 | 0.030 |
Why?
| | Computational Biology | 1 | 2016 | 212 | 0.030 |
Why?
| | Arteries | 1 | 1995 | 92 | 0.030 |
Why?
| | Cytokines | 1 | 2017 | 623 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 17 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2009 | 591 | 0.030 |
Why?
| | Treatment Failure | 2 | 2008 | 122 | 0.030 |
Why?
| | Dementia | 1 | 1995 | 134 | 0.030 |
Why?
| | Missouri | 2 | 2006 | 66 | 0.030 |
Why?
| | Inclusion Bodies | 1 | 1993 | 17 | 0.030 |
Why?
| | Organs at Risk | 1 | 2014 | 75 | 0.030 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 1993 | 23 | 0.030 |
Why?
| | Cell Division | 2 | 1994 | 291 | 0.030 |
Why?
| | Cell Death | 1 | 2014 | 177 | 0.030 |
Why?
| | Cholera Toxin | 1 | 1993 | 16 | 0.030 |
Why?
| | Cholera | 1 | 1993 | 2 | 0.030 |
Why?
| | Risk | 2 | 2004 | 316 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2014 | 154 | 0.030 |
Why?
| | Skin Physiological Phenomena | 1 | 1992 | 15 | 0.020 |
Why?
| | Guinea Pigs | 1 | 1992 | 75 | 0.020 |
Why?
| | Pelvis | 2 | 2004 | 69 | 0.020 |
Why?
| | Epidermis | 1 | 1992 | 32 | 0.020 |
Why?
| | Pedigree | 2 | 2004 | 125 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2012 | 35 | 0.020 |
Why?
| | Regeneration | 1 | 1992 | 79 | 0.020 |
Why?
| | Colectomy | 1 | 1992 | 35 | 0.020 |
Why?
| | Computer Simulation | 1 | 2012 | 290 | 0.020 |
Why?
| | Sequence Deletion | 2 | 2003 | 73 | 0.020 |
Why?
| | Premenopause | 1 | 2010 | 27 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 578 | 0.020 |
Why?
| | Staurosporine | 1 | 2010 | 13 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 1990 | 68 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 82 | 0.020 |
Why?
| | Remission Induction | 1 | 2010 | 218 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2001 | 69 | 0.020 |
Why?
| | ras Proteins | 2 | 2001 | 64 | 0.020 |
Why?
| | Cicatrix | 1 | 1990 | 42 | 0.020 |
Why?
| | Staining and Labeling | 1 | 1990 | 97 | 0.020 |
Why?
| | Hemoglobins | 1 | 1990 | 112 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 288 | 0.020 |
Why?
| | Perioperative Care | 1 | 2009 | 43 | 0.020 |
Why?
| | Fetus | 1 | 1990 | 194 | 0.020 |
Why?
| | Urinary Incontinence | 1 | 2009 | 40 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2008 | 14 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 108 | 0.020 |
Why?
| | Vinblastine | 1 | 2008 | 23 | 0.020 |
Why?
| | Life Style | 1 | 2009 | 145 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 184 | 0.020 |
Why?
| | Emotions | 1 | 2009 | 174 | 0.020 |
Why?
| | Cadherins | 1 | 2007 | 62 | 0.020 |
Why?
| | Demography | 1 | 2007 | 90 | 0.020 |
Why?
| | Cell Line | 1 | 1990 | 1030 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 134 | 0.020 |
Why?
| | Cytoplasmic Structures | 1 | 2006 | 1 | 0.020 |
Why?
| | DNA Mismatch Repair | 1 | 2006 | 18 | 0.020 |
Why?
| | Tissue Embedding | 1 | 2006 | 1 | 0.020 |
Why?
| | Skin | 1 | 1990 | 422 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2006 | 17 | 0.020 |
Why?
| | Waxes | 1 | 2006 | 2 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 51 | 0.020 |
Why?
| | Immunoenzyme Techniques | 2 | 2001 | 137 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2006 | 11 | 0.020 |
Why?
| | Chromosomal Instability | 1 | 2006 | 16 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 173 | 0.020 |
Why?
| | Cryopreservation | 1 | 2006 | 41 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2007 | 554 | 0.020 |
Why?
| | Transfection | 1 | 2006 | 357 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2006 | 108 | 0.020 |
Why?
| | Gene Expression | 1 | 2008 | 618 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 2006 | 44 | 0.020 |
Why?
| | Gynecology | 1 | 2006 | 52 | 0.020 |
Why?
| | Medical Futility | 1 | 2005 | 8 | 0.020 |
Why?
| | Ovarian Cysts | 1 | 2005 | 4 | 0.020 |
Why?
| | Sarcoma, Endometrial Stromal | 1 | 2005 | 1 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2006 | 95 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2006 | 171 | 0.020 |
Why?
| | Triage | 1 | 2006 | 66 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2005 | 21 | 0.020 |
Why?
| | Hospice Care | 1 | 2005 | 26 | 0.010 |
Why?
| | Health Services | 1 | 2005 | 65 | 0.010 |
Why?
| | Cytodiagnosis | 1 | 2005 | 43 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 528 | 0.010 |
Why?
| | Obstetrics | 1 | 2006 | 89 | 0.010 |
Why?
| | Lymphatic System | 1 | 2004 | 16 | 0.010 |
Why?
| | Penetrance | 1 | 2004 | 7 | 0.010 |
Why?
| | Area Under Curve | 1 | 2004 | 180 | 0.010 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2004 | 78 | 0.010 |
Why?
| | Calcification, Physiologic | 1 | 2004 | 42 | 0.010 |
Why?
| | Laparotomy | 1 | 2004 | 37 | 0.010 |
Why?
| | Bryostatins | 1 | 2003 | 1 | 0.010 |
Why?
| | Macrolides | 1 | 2003 | 17 | 0.010 |
Why?
| | Ethanol | 1 | 2006 | 342 | 0.010 |
Why?
| | Genomic Instability | 1 | 2004 | 89 | 0.010 |
Why?
| | Tamoxifen | 1 | 2004 | 60 | 0.010 |
Why?
| | Thrombospondin 1 | 1 | 2003 | 7 | 0.010 |
Why?
| | Genes, p16 | 1 | 2003 | 9 | 0.010 |
Why?
| | Codon, Terminator | 1 | 2003 | 8 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 158 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 2003 | 18 | 0.010 |
Why?
| | Liposomes | 1 | 2003 | 54 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 451 | 0.010 |
Why?
| | Mutagenesis, Insertional | 1 | 2003 | 24 | 0.010 |
Why?
| | Body Weight | 1 | 2005 | 523 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 2003 | 48 | 0.010 |
Why?
| | Palliative Care | 1 | 2005 | 214 | 0.010 |
Why?
| | Physicians | 1 | 2006 | 241 | 0.010 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 107 | 0.010 |
Why?
| | Prevalence | 1 | 2006 | 1006 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 313 | 0.010 |
Why?
| | beta Catenin | 1 | 2003 | 102 | 0.010 |
Why?
| | Retinoblastoma-Like Protein p130 | 1 | 2002 | 8 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2002 | 19 | 0.010 |
Why?
| | Ifosfamide | 1 | 2002 | 9 | 0.010 |
Why?
| | Documentation | 1 | 2002 | 33 | 0.010 |
Why?
| | Trans-Activators | 1 | 2003 | 135 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 38 | 0.010 |
Why?
| | Hospitals, University | 1 | 2002 | 75 | 0.010 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2002 | 77 | 0.010 |
Why?
| | Equipment Failure | 1 | 2001 | 64 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 174 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 192 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 2 | 1991 | 56 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2002 | 80 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 2001 | 26 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 470 | 0.010 |
Why?
| | Genes, erbB-1 | 1 | 2001 | 9 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 125 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 736 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2000 | 90 | 0.010 |
Why?
| | DNA | 1 | 2004 | 549 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2001 | 155 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2000 | 25 | 0.010 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2000 | 25 | 0.010 |
Why?
| | Morbidity | 1 | 2000 | 145 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 590 | 0.010 |
Why?
| | Gene Deletion | 1 | 2000 | 272 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 170 | 0.010 |
Why?
| | Chromosomes, Bacterial | 1 | 1998 | 5 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 190 | 0.010 |
Why?
| | Infant | 1 | 2006 | 3733 | 0.010 |
Why?
| | Child, Preschool | 1 | 2006 | 4076 | 0.010 |
Why?
| | Drug Resistance, Multiple | 1 | 1997 | 24 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 1997 | 71 | 0.010 |
Why?
| | Gene Frequency | 1 | 1997 | 98 | 0.010 |
Why?
| | United States | 1 | 2007 | 5192 | 0.010 |
Why?
| | Hygiene | 1 | 1995 | 11 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 1995 | 111 | 0.010 |
Why?
| | Dimethyl Sulfoxide | 1 | 1994 | 12 | 0.010 |
Why?
| | Glycerol | 1 | 1994 | 19 | 0.010 |
Why?
| | Ambulatory Surgical Procedures | 1 | 1995 | 52 | 0.010 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 136 | 0.010 |
Why?
| | Drug Carriers | 1 | 1994 | 73 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 230 | 0.010 |
Why?
| | H-2 Antigens | 1 | 1993 | 4 | 0.010 |
Why?
| | Caregivers | 1 | 1995 | 240 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1993 | 74 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1993 | 163 | 0.010 |
Why?
| | Retroperitoneal Space | 1 | 1991 | 26 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1993 | 1478 | 0.000 |
Why?
|
|
Rader's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|